AKEBIA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.075 USD | -2.27% |
|
-4.82% | -12.50% |
| 05-09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
| Sales 2024 * | 173M 13.59B | Sales 2025 * | 159M 12.55B | Capitalization | 231M 18.16B |
|---|---|---|---|---|---|
| Net income 2024 * | -64M -5.04B | Net income 2025 * | -73M -5.75B | EV / Sales 2024 * | 1.34 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.45 x |
| P/E ratio 2024 * |
-4.23
x | P/E ratio 2025 * |
-3.37
x | Employees | 167 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akebia Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -2.27% | ||
| 1 week | -4.82% | ||
| Current month | -13.89% | ||
| 1 month | -20.80% | ||
| 3 months | -19.63% | ||
| 6 months | +8.50% | ||
| Current year | -12.50% |
1 week
1.08
1.20
1 month
1.031.56
Current year
1.032.48
1 year
0.782.48
3 years
0.244.33
5 years
0.2413.71
10 years
0.2431.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 30/06/13 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 31/03/22 |
Michel Dahan
COO | Chief Operating Officer | 45 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 11/12/18 |
Adrian Adams
CHM | Chairman | 73 | 11/12/18 |
LeAnne Zumwalt
BRD | Director/Board Member | 65 | 15/02/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/05/24 | 1.085 | -1.36% | 821 785 |
| 22/05/24 | 1.1 | -2.65% | 1,810,178 |
| 21/05/24 | 1.13 | -1.74% | 3,374,528 |
| 20/05/24 | 1.15 | 0.00% | 2,384,758 |
| 17/05/24 | 1.15 | +0.88% | 2,392,797 |
Delayed Quote Nasdaq, May 23, 2024 at 07:00 pm
More quotes
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Companyâs portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Calendar
06/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.1
USD
Average target price
5
USD
Spread / Average Target
+354.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.50% | 231M | |
| +10.51% | 115B | |
| +12.16% | 106B | |
| -4.56% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.45% | 17.56B | |
| -40.50% | 17.32B | |
| +6.05% | 14.03B | |
| +30.58% | 12.13B |
- Stock Market
- Equities
- AKBA Stock
